Multiplex Spatial Proteomic Analysis of HER2–Positive Breast Tumors Reveals Unique Molecular and Immunologic Features Associated With Treatment Response
Hennessy M, Cimino-Mathews A, Carter J, Kachergus J, Ma Y, Leal J, Solnes L, Denbow R, Abramson V, Carey L, Rimawi M, Specht J, Storniolo A, Valero V, Vaklavas C, Winer E, Krop I, Wolff A, Wahl R, Perez E, Huang C, Stearns V, Thompson E, Connolly R. Multiplex Spatial Proteomic Analysis of HER2–Positive Breast Tumors Reveals Unique Molecular and Immunologic Features Associated With Treatment Response. JCO Precision Oncology 2025, 9: e2400546. PMID: 40179327, PMCID: PMC11968088, DOI: 10.1200/po-24-00546.Peer-Reviewed Original ResearchConceptsPrediction of pathological complete responseHER2-positive breast cancerBreast cancerAbundant tumorHematoxylin and eosin and immunohistochemistryClinical trialsEstrogen receptor (ER)-negativeStromal tumor-infiltrating lymphocytesHuman epidermal growth factor 2 (HER2)-positive breast cancerPathological complete responseTumor-infiltrating lymphocytesEpidermal growth factor receptor signalingImmune cell activationDigital spatial profilingImmune-based biomarkersGeoMx Digital Spatial ProfilerNanoString GeoMx Digital Spatial ProfilingGrowth factor receptor signalingBaseline Ki67Baseline tumorsComplete responseER-negativeBasal-likeTumor biopsiesImmunological features
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply